ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Economy

Sanofi to refocus R&D, cut jobs in France and Germany

by Michael McCoy
June 21, 2019 | APPEARED IN VOLUME 97, ISSUE 25

 

Sanofi plans to reduce its R&D staff of about 10,000 by 466 positions in France and Germany as part of a program to sharpen its research focus. Sanofi’s research priorities will be oncology, immunology, rare diseases, and vaccines. The French drugmaker says it will end new R&D in cardiovascular therapy, continuing only current programs. In diabetes research it will focus on treatments that address the underlying causes of the disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment